TNAs, or therapeutic nucleic acids, are nucleic acids or closely related compounds that are used to cure disease. TNAs come in a variety of shapes and sizes, but they all have the same mode of action: sequence specific recognition of endogenous nucleic acids via Watson–Crick base pairing. The growing number of FDA-approved nucleic acid therapies shows that diseases can be treated in vivo by addressing their genetic blueprints. Because they target proteins rather than the underlying reasons, traditional therapies typically have transitory therapeutic results. Nucleic acid treatments, on the other hand, can achieve long-lasting or even curative effects by inhibiting, replacing, or altering genes. However, delivery strategies that improve stability, enable internalisation, and boost target affinity are required for clinical translation. Synthetic biology, systems biology, computational biology, bioinformatics, and nanotechnology, among other fields, have accelerated progress and established a new paradigm for nucleic acids in therapy.
Title : Eliminating implant infection: 30,000 nanotextured implants in humans with no failure
Thomas J Webster, Interstellar Therapeutics, United States
Title : Information leakage: Types, remedies, and open problems
Julia Sidorova, Centro de Investigación Biomédica En Red Enfermedades Hepáticas y Digestivas (CIBEREHD), Spain
Title : Biotech innovations: Bioengineering potential for novel biomanufacturing systems
Murray Moo Young, University of Waterloo, Canada
Title : Development and characterization of exo-ITC: A fibrous bilayer exosome delivery system for dermatological applications
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico
Title : Targeting noncanonical epitopes in anti-cancer immunotherapy
Michele Mishto, Francis Crick Institute, United Kingdom
Title : Stem cell therapy: An affordable healthcare therapy for various diseases
Anant Marathe, Total Potential Cells (P) Ltd, India